Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 14, 2013; 19(22): 3481-3486
Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3481
Table 2 Comparison of change in hepatic and renal function between two treatment groups (mean ± SD)
CharacteristicsDe novo combination group
Lamivudine monotherapy group
Baseline48 wk96 wk144 wkBaseline48 wk96 wk144 wk
Hepatic function
Albumin (g/dL)3.2 ± 0.73.5 ± 0.43.8 ± 0.14.1 ± 0.3a3.3 ± 0.63.4 ± 0.33.6 ± 0.83.8 ± 0.3c
TBIL (μmol/L)38.5 ± 12.124.3 ± 11.420.4 ± 10.816.1 ± 6.7a37.8 ± 11.926.5 ± 12.323.2 ± 10.518.1 ± 12.3
PT (s)17.1 ± 4.514.5 ± 5.313.3 ± 9.1a11.4 ± 5.8a17.6 ± 3.115.4 ± 3.514.5 ± 6.913.4 ± 5.8c
CTP score8.9 ± 2.17.0 ± 1.26.3 ± 2.7a5.7 ± 1.9a8.8 ± 1.77.6 ± 2.46.6 ± 1.96.1 ± 3.8
MELD score12.4 ± 3.710.0 ± 6.59.6 ± 5.38.8 ± 2.7a11.9 ± 2.510.8 ± 3.78.9.7 ± 4.88.9 ± 4.3
Renal function
BUN (mmol/L)6.7 ± 0.76.8 ± 1.47.1 ± 1.16.9 ± 0.36.8 ± 0.67.4 ± 1.37.2 ± 0.87.0 ± 1.1
Cr (μmol/L)96.1 ± 12.398.3 ± 8.997.8 ± 10.799.7 ± 9.695.6 ± 12.197.8 ± 7.998.6 ± 12.799.5 ± 9.7
GFR (mL/min)115.2 ± 34.5112.8 ± 56.3103.4 ± 76.1109.1 ± 21.5113.5 ± 22.9107.6 ± 13.4112.4 ± 45.5109.4 ± 13.4